Altamira's Drug-Free Nasal Spray Shows Benefit In House Dust Mite Study

  • Altamira Therapeutics Ltd CYTO announced topline data from its clinical trial with Bentrio nasal spray in house dust mite (HDM) allergic rhinitis.
  • The HDM challenge trial demonstrated a statistically significant reduction of nasal symptoms vs. untreated controls and good tolerability and safety. 
  • Bentrio is a drug-free nasal spray intended for personal protection against airborne viruses and allergens with a triple mode of action.
  • At a single Canadian study site, the trial enrolled 37 patients. 
  • Read Next: Why Are Altamira Therapeutics Shares Gaining Today?
  • Under Bentrio treatment, the mean Total Nasal Symptom Score (TNSS) was 4.1 points vs. 5.2 points under no treatment.
  • The changes in TNSS started to separate at the 40-minute time point and, on average, reached 1.5 to 2 points from the mid-point to the end of the exposure.
  • The protective effect was observed with a single or double puff per nostril with no meaningful difference between the two treatment approaches. 
  • Regarding safety, there were only a few adverse events, mostly mild, and more than 85% of study participants rated the tolerability of Bentrio as "good" or "very good."
  • Price Action: CYTO shares are up 9.39% at $0.94 during the market session on the last check Friday.
Posted In: BriefsBiotechNewsPenny StocksHealth CareMoversTrading IdeasGeneral